Assess whether RWE can replace or only supplement an RCT (94b466)

Situation

A competitor label that just got a narrower indication put disproportionate reporting signal workbook in front of pharmacovigilance medical reviewer in a rare-disease team designing a pediatric plan. This Pharma & Life Sciences / Clinical and Evidence Strategy close is RWE can replace or from disproportionate reporting signal workbook, and the live options are RWE can replace, Only supplement an RCT.

Decision

Pharmacovigilance medical reviewer in a rare-disease team designing a pediatric plan must choose RWE can replace / Only supplement an RCT using disproportionate reporting signal workbook after a competitor label that just got a narrower indication.

Hypotheses to test

• Disproportionate reporting signal workbook reads as RWE can replace once a competitor label that just got a narrower indication is lined up to the same Pharma & Life Sciences population.
• Disproportionate reporting signal workbook is closer to Only supplement an RCT after a competitor label that just got a narrower indication; RWE can replace would over-claim this Clinical and Evidence Strategy extract.
• A dual reading is still live in disproportionate reporting signal workbook for pharmacovigilance medical reviewer in a rare-disease team designing a pediatric plan.
• Disproportionate reporting signal workbook is missing the fact pharmacovigilance medical reviewer needs after a competitor label that just got a narrower indication; stop this Pharma & Life Sciences close.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on RWE can replace or.
• Check whether disproportionate reporting signal workbook supports the labeled claim pharmacovigilance medical reviewer would keep.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against a competitor label that just got a narrower indication and write the one fact that would move RWE can replace or for pharmacovigilance medical reviewer.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (disproportionate reporting signal workbook after a competitor label that just got a narrower indication). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after a competitor label that just got a narrower indication, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a rare-disease team designing a pediatric plan.